A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)

The A5414 study will evaluate whether treatment for drug-susceptible pulmonary tuberculosis (TB) can be tailored according to a participant's risk of an unfavorable outcome. Participants will be assigned to lower-risk or higher-risk groups using baseline characteristics and then randomized within each group to receive either standard TB treatment or an investigational rifapentine- and moxifloxacin-containing regimen. The study will evaluate whether shorter treatment durations may be used in lower-risk participants and whether the investigational regimen may improve outcomes in higher-risk participants. Safety and tolerability will also be evaluated.

NCT Number	NCT07595042
Lead Sponsor	National Institute of Allergy and Infectious Diseases (NIAID) Collaborators: ViiV Healthcare
Conditions	Tuberculosis
Enrollment	900 participants
Start Date	2026-07-31
Primary Completion	2029-06-05 (estimated)
Study Completion	2029-10-22 (estimated)
Updated on ClinicalTrials.gov	2026-06-15